Your browser doesn't support javascript.
loading
Interleukin-34-orchestrated tumor-associated macrophage reprogramming is required for tumor immune escape driven by p53 inactivation.
Nian, Zhigang; Dou, Yingchao; Shen, Yiqing; Liu, Jintang; Du, Xianghui; Jiang, Yong; Zhou, Yonggang; Fu, Binqing; Sun, Rui; Zheng, Xiaohu; Tian, Zhigang; Wei, Haiming.
Afiliação
  • Nian Z; Department of Geriatrics, First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei 230036, China; Key Laboratory of Immune Response and Immunotherapy, School of Basic Medical Sciences, Division of Life Sciences and Medicine, Univ
  • Dou Y; Key Laboratory of Immune Response and Immunotherapy, School of Basic Medical Sciences, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China; Institue of Immunology, University of Science and Technology of China, Hefei, Anhui 230027, China.
  • Shen Y; Key Laboratory of Immune Response and Immunotherapy, School of Basic Medical Sciences, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China; Institue of Immunology, University of Science and Technology of China, Hefei, Anhui 230027, China.
  • Liu J; Key Laboratory of Immune Response and Immunotherapy, School of Basic Medical Sciences, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China; Institue of Immunology, University of Science and Technology of China, Hefei, Anhui 230027, China.
  • Du X; Key Laboratory of Immune Response and Immunotherapy, School of Basic Medical Sciences, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China; Institue of Immunology, University of Science and Technology of China, Hefei, Anhui 230027, China.
  • Jiang Y; Department of Anesthesiology, The first affiliated hospital of Anhui Medical University, Hefei, Anhui 230027, China.
  • Zhou Y; Key Laboratory of Immune Response and Immunotherapy, School of Basic Medical Sciences, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China; Institue of Immunology, University of Science and Technology of China, Hefei, Anhui 230027, China.
  • Fu B; Key Laboratory of Immune Response and Immunotherapy, School of Basic Medical Sciences, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China; Institue of Immunology, University of Science and Technology of China, Hefei, Anhui 230027, China.
  • Sun R; Key Laboratory of Immune Response and Immunotherapy, School of Basic Medical Sciences, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China; Institue of Immunology, University of Science and Technology of China, Hefei, Anhui 230027, China.
  • Zheng X; Key Laboratory of Immune Response and Immunotherapy, School of Basic Medical Sciences, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China; Institue of Immunology, University of Science and Technology of China, Hefei, Anhui 230027, China.
  • Tian Z; Key Laboratory of Immune Response and Immunotherapy, School of Basic Medical Sciences, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China; Institue of Immunology, University of Science and Technology of China, Hefei, Anhui 230027, China.
  • Wei H; Department of Geriatrics, First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei 230036, China; Key Laboratory of Immune Response and Immunotherapy, School of Basic Medical Sciences, Division of Life Sciences and Medicine, Univ
Immunity ; 57(10): 2344-2361.e7, 2024 Oct 08.
Article em En | MEDLINE | ID: mdl-39321806
ABSTRACT
As the most frequent genetic alteration in cancer, more than half of human cancers have p53 mutations that cause transcriptional inactivation. However, how p53 modulates the immune landscape to create a niche for immune escape remains elusive. We found that cancer stem cells (CSCs) established an interleukin-34 (IL-34)-orchestrated niche to promote tumorigenesis in p53-inactivated liver cancer. Mechanistically, we discovered that Il34 is a gene transcriptionally repressed by p53, and p53 loss resulted in IL-34 secretion by CSCs. IL-34 induced CD36-mediated elevations in fatty acid oxidative metabolism to drive M2-like polarization of foam-like tumor-associated macrophages (TAMs). These IL-34-orchestrated TAMs suppressed CD8+ T cell-mediated antitumor immunity to promote immune escape. Blockade of the IL-34-CD36 axis elicited antitumor immunity and synergized with anti-PD-1 immunotherapy, leading to a complete response. Our findings reveal the underlying mechanism of p53 modulation of the tumor immune microenvironment and provide a potential target for immunotherapy of cancer with p53 inactivation.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Proteína Supressora de Tumor p53 / Interleucinas / Evasão Tumoral / Microambiente Tumoral / Macrófagos Associados a Tumor Limite: Animals / Humans Idioma: En Revista: Immunity Assunto da revista: ALERGIA E IMUNOLOGIA Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Proteína Supressora de Tumor p53 / Interleucinas / Evasão Tumoral / Microambiente Tumoral / Macrófagos Associados a Tumor Limite: Animals / Humans Idioma: En Revista: Immunity Assunto da revista: ALERGIA E IMUNOLOGIA Ano de publicação: 2024 Tipo de documento: Article